• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ASP Isotopes and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

    10/20/23 9:00:00 AM ET
    $ASPI
    $SNGX
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASPI alert in real time by email

    ORLANDO, FL / ACCESSWIRE / October 20, 2023 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and Soligenix, Inc. (NASDAQ:SNGX) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, October 21, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

    Access the interviews in their entirety at:

    • ASP Isotopes: https://www.redchip.com/assets/access/aspi_access
    • Soligenix: https://www.redchip.com/assets/access/sngx_access

    Paul Mann, CEO, of ASP Isotopes appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a corporate update. ASP Isotopes successfully acquired two incomplete ASP plants in Pretoria, South Africa, and obtained the required licenses from the nuclear regulators, including the Non-proliferation Council of South Africa, to complete construction of the plants and produce commercial product. Cold commissioning of the first manufacturing plant, capable of enriching light isotopes, was completed in Q1 2023, and ASP Isotopes entered into a Memorandum of Understanding with a North American customer for the entire offtake of the Company's first light isotope plant. The Company intends to enter into "take or pay" style offtake agreements with customers, and by 2028, ASP Isotopes expects to be a leading supplier of nonnuclear enriched isotopes generating over $150M in EBITDA per annum. ASP Isotopes has secured multiple supply agreements, including a 25- year agreement valued at up to $27M per annum with BRICEM (Beijing Research Institute of Chemical Engineering Metallurgy) to supply highly enriched Molybdenum-100 (Mo-100); a multi-year agreement with a Canadian company valued at $3.8M per annum for C-14, the most frequently used radiolabel healthcare; a $9M supply agreement with a US customer for a highly enriched isotope - customer made a $900k prepayment during Q3 2023; and an MOU for HALEU - $30 billion of HALEU demand expected based on initial discussions with customers.

    Also appearing on the RedChip Small Stocks Big Money® Show this week is Dr. Chris Schaber, CEO of Soligenix. Soligenix, a late-stage biopharmaceutical company, offers a robust pipeline of multiple fast-track and orphan-designated products with the potential for significant commercial returns of approximately $2 billion in global annual sales. Soligenix's late-stage clinical assets include HyBryte™ (SGX301), a photodynamic therapy for the treatment of cutaneous T-cell lymphoma (CTCL). The positive statistically significant results achieved in the Phase 3 study of HyBryte have been published in JAMA Dermatology, and the Company is preparing to meet with the FDA to discuss the design of the second confirmatory Phase 3 study. The estimated global market potential for HyBryte is $250 million, making it a significant commercial opportunity in an area of unmet medical need.

    About ASP Isotopes Inc.

    ASP Isotopes Inc. is an advanced materials company dedicated to developing technology and processes to produce isotopes in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process ("ASP technology"), for the production of all isotopes. The Company's initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes).

    There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy applications. The ASP Technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass molecules. For more information, please visit www.aspisotopes.com.

    About Soligenix

    Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203).

    Our Public Health Solutions business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).

    For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com.

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Small Stocks Big Money® Show is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Small Stocks Big Money® Show," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
    Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
    Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
    Follow RedChip on Twitter: https://twitter.com/RedChip
    Follow RedChip on YouTube: https://www.youtube.com/@redchip
    Follow RedChip on Rumble: https://rumble.com/c/c-3068340

    Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-800-RED-CHIP (733-2447)
    Or 407-491-4498
    [email protected]

    SOURCE: RedChip Companies Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/794956/asp-isotopes-and-soligenix-interviews-to-air-on-the-redchip-small-stocks-big-moneyr-show-on-bloomberg-tv

    Get the next $ASPI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ASPI
    $SNGX

    CompanyDatePrice TargetRatingAnalyst
    ASP Isotopes Inc.
    $ASPI
    10/4/2024$4.50Buy
    Canaccord Genuity
    ASP Isotopes Inc.
    $ASPI
    12/5/2023$3.25Buy
    H.C. Wainwright
    More analyst ratings

    $ASPI
    $SNGX
    Leadership Updates

    Live Leadership Updates

    See more
    • ASP Isotopes Inc. Enhances Executive Leadership Team with the Appointment of Heather Kiessling as Chief Financial Officer

      WASHINGTON, June 13, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced the appointment of Heather Kiessling as its chief financial officer (CFO), effective as of July 1, 2024 (or such earlier date as may be mutually agreed), to support the Company's next pivotal phase of growth. Robert Ainscow, who currently serves as the Company's CFO and chief operating officer (COO), will continue to serve as the Company's COO, enabling him to focus his full time and attention on the Company's operat

      6/13/24 10:56:52 AM ET
      $ASPI
      Major Chemicals
      Industrials
    • Professor Mike Gorley From UK Atomic Energy Authority to Join Board of Directors of ASP Isotopes Inc.

      WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASPI", the "Company", "us", "we" or "our"), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes for use in multiple industries, today announced that Professor Mike Gorley, Chief Technologist at the UK Atomic Energy Authority is to join the board of directors of the Company. Professor Gorley is Chief Technologist at the UK Atomic Energy Authority and a visiting Professor at the University of Bristol, U.K. He is a well-known expert in fusion technology and fusion materials. In 2014, Mike was awarded a Ph.D. (DPhil) in Materials Science from Oxford

      10/19/23 8:00:00 AM ET
      $ASPI
      Major Chemicals
      Industrials
    • Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders

      PRINCETON, N.J., Sept. 22, 2023 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2023 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for and convened on September 21, 2023 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission (the "SEC") on August 7, 2023 (the "Proxy Statement"). As a result of the additional ti

      9/22/23 4:00:00 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASPI
    $SNGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

      PRINCETON, N.J., May 9, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2025. "Our strategic focus remains on advancing our clinical programs, and we anticipate several significant development milestones. These include top-line results in 2026 from our actively enrolling Phase 3 confirmatory study of Hy

      5/9/25 7:30:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc.

      AUSTIN, Texas, May 07, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Christopher Schaber, Chairman, President, and CEO of Soligenix Inc. (NASDAQ:SNGX), a late-stage biopharmaceutical company focused on developing and commercializ

      5/7/25 8:00:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASP Isotopes Inc. Announces Proposed Secondary Listing on the Johannesburg Stock Exchange

      WASHINGTON , April 24, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, is pleased to announce the proposed secondary listing of the Company's common stock by way of introduction on the Main Board of the Johannesburg Stock Exchange ("JSE").   The Company's common stock will continue to be listed and traded on the Nasdaq Capital Market. ASPI's history and technology is firmly rooted in South Africa and has been developed over four years by the Company's highly skilled South African team members. Furth

      4/24/25 8:00:00 AM ET
      $ASPI
      Major Chemicals
      Industrials

    $ASPI
    $SNGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ASPI
    $SNGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ASPI
    $SNGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ASPI
    $SNGX
    Financials

    Live finance-specific insights

    See more
    • Chief Operating Officer Ainscow Robert bought 19,992 shares, increasing direct ownership by 2% to 919,992 units (SEC Form 4)

      4 - ASP Isotopes Inc. (0001921865) (Issuer)

      7/15/24 10:33:49 AM ET
      $ASPI
      Major Chemicals
      Industrials
    • Chief Executive Officer Mann Paul Elliot bought 39,984 shares, increasing direct ownership by 0.69% to 5,845,627 units (SEC Form 4)

      4 - ASP Isotopes Inc. (0001921865) (Issuer)

      7/15/24 10:33:33 AM ET
      $ASPI
      Major Chemicals
      Industrials
    • Large owner Ak Jensen Investment Management Ltd bought $515,088 worth of shares (161,849 units at $3.18) (SEC Form 4)

      4 - ASP Isotopes Inc. (0001921865) (Issuer)

      7/10/24 5:59:47 PM ET
      $ASPI
      Major Chemicals
      Industrials
    • Canaccord Genuity initiated coverage on ASP Isotopes with a new price target

      Canaccord Genuity initiated coverage of ASP Isotopes with a rating of Buy and set a new price target of $4.50

      10/4/24 7:13:36 AM ET
      $ASPI
      Major Chemicals
      Industrials
    • H.C. Wainwright initiated coverage on ASP Isotopes with a new price target

      H.C. Wainwright initiated coverage of ASP Isotopes with a rating of Buy and set a new price target of $3.25

      12/5/23 7:36:42 AM ET
      $ASPI
      Major Chemicals
      Industrials
    • SEC Form SC 13G filed by ASP Isotopes Inc.

      SC 13G - ASP Isotopes Inc. (0001921865) (Subject)

      11/14/24 3:01:19 PM ET
      $ASPI
      Major Chemicals
      Industrials
    • Amendment: SEC Form SC 13G/A filed by ASP Isotopes Inc.

      SC 13G/A - ASP Isotopes Inc. (0001921865) (Subject)

      11/7/24 4:15:14 PM ET
      $ASPI
      Major Chemicals
      Industrials
    • SEC Form SC 13G filed by ASP Isotopes Inc.

      SC 13G - ASP Isotopes Inc. (0001921865) (Subject)

      11/3/23 4:15:20 PM ET
      $ASPI
      Major Chemicals
      Industrials
    • Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 20, 2024 / RedChip Companies will air interviews with Nova Minerals Limited (NASDAQ:NVA) and Soligenix Inc. (NASDAQ:SNGX) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, September 21, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nova Minerals: https://www.redchip.com/assets/access/nva_accessSoligenix: https://www.redchip.com/assets/access/sngx_accessChristopher Gerteisen, CEO of Nova Minerals, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Nova Minerals p

      9/20/24 9:00:00 AM ET
      $BOXL
      $NVA
      $SNGX
      Other Consumer Services
      Real Estate
      Precious Metals
      Basic Materials
    • Mobilicom and ASP Isotopes Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 13, 2024 / RedChip Companies will air interviews with Mobilicom Ltd. (NASDAQ:MOB) and ASP Isotopes Inc. (NASDAQ:ASPI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, September 14, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Mobilicom: https://www.redchip.com/assets/access/mob_accessASP Isotopes: https://www.redchip.com/assets/access/aspi_accessOren Elkayam, Founder and CEO of Mobilicom, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Mobilicom presents a

      9/13/24 9:00:00 AM ET
      $ASPI
      $BOXL
      $MOB
      Major Chemicals
      Industrials
      Other Consumer Services
      Real Estate
    • Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / August 16, 2024 / RedChip Companies will air interviews with Soligenix Inc. (NASDAQ:SNGX) and American Resources Corp. (NASDAQ:AREC) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 17, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix: https://www.redchip.com/assets/access/sngx_accessAmerican Resources: https://www.redchip.com/assets/access/arec_accessIn an exclusive interview, Christopher J. Schaber, PhD, President and CEO of Soligenix, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV

      8/16/24 9:00:00 AM ET
      $AREC
      $SNGX
      Coal Mining
      Energy
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASPI
    $SNGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Ainscow Robert sold $1,121,347 worth of shares (200,000 units at $5.61), decreasing direct ownership by 12% to 1,419,992 units (SEC Form 4)

      4 - ASP Isotopes Inc. (0001921865) (Issuer)

      4/17/25 7:57:41 PM ET
      $ASPI
      Major Chemicals
      Industrials
    • Chief Executive Officer Mann Paul Elliot sold $5,326,397 worth of shares (950,000 units at $5.61), decreasing direct ownership by 11% to 7,315,454 units (SEC Form 4)

      4 - ASP Isotopes Inc. (0001921865) (Issuer)

      4/17/25 7:57:18 PM ET
      $ASPI
      Major Chemicals
      Industrials
    • Chief Operating Officer Ainscow Robert was granted 400,000 shares, increasing direct ownership by 33% to 1,619,992 units (SEC Form 4)

      4 - ASP Isotopes Inc. (0001921865) (Issuer)

      4/15/25 8:42:42 AM ET
      $ASPI
      Major Chemicals
      Industrials

    $ASPI
    $SNGX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Soligenix Inc.

      10-Q - SOLIGENIX, INC. (0000812796) (Filer)

      5/9/25 4:05:33 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Soligenix Inc.

      DEFA14A - SOLIGENIX, INC. (0000812796) (Filer)

      5/5/25 4:09:41 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Soligenix Inc.

      DEF 14A - SOLIGENIX, INC. (0000812796) (Filer)

      5/5/25 4:05:36 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care